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The reactivation or reexpression of telomerase (TERT) is a widespread feature of neoplasms. TERT promoter
mutations were recently reported that were hypothesized to result from UV radiation. In this retrospective study,
we assessed TERT promoter mutations in 196 cutaneous basal cell carcinomas (BCCs), including 102 tumors from
X-irradiated patients, 94 tumors from patients never exposed to ionizing radiation treatment, and 116 melanomas.
We sought to evaluate the effects of UV and X-ray irradiation on TERTmutation frequency. TERTmutations were
detected in 27% of BCCs from X-irradiated patients, 51% of BCCs from nonirradiated patients, and 22% of
melanoma patients. TERTmutations were significantly increased in non-X-irradiated BCC patients compared with
X-irradiated BCC patients; the mutations also presented a different mutation signature. In nonirradiated patients,
TERT mutations were more frequent in BCCs of sun-exposed skin, supporting a possible causative role of UV
radiation. In melanoma, TERT promoter mutations were generally restricted to intermittent sun-exposed areas
and were associated with nodular and superficial spreading subtypes, increased thickness, ulceration, increased
mitotic rate, and BRAFV600E mutations. Our results suggest that various carcinogenic factors may cause distinct
TERT promoter mutations in BCC and that TERT promoter mutations might be associated with a poorer prognosis
in melanoma.
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INTRODUCTION
Telomerase (TERT) is a ribonucleoprotein complex that
synthesizes telomeric DNA responsible for maintaining telo-
mere length at chromosome ends (Chiu and Harley, 1997). It
is well established that TERT reactivation is associated with
carcinogenesis and represents an important step toward tumor
immortalization (Shay and Wright, 1996). TERT promoter
mutations have recently been described in distinct human
tumors (Horn et al., 2013; Huang et al., 2013; Killela et al.,
2013; Vinagre et al., 2013); these mutations are particularly
prevalent in melanoma, basal cell carcinoma (BCC), and
squamous cell carcinoma (tongue and skin), and they
enhance TERT promoter activity (Griewank et al., 2013;
Horn et al., 2013; Huang et al., 2013; Killela et al., 2013;
Scott et al., 2013). The mutations are cytidine to thymidine
transitions at dipyrimidine motifs, implying a putative UV
light–induced damage signature that creates a new binding
consensus for ETS/TCFs transcription factors (Horn et al.,
2013; Huang et al., 2013).
Melanoma originates from the malignant transformation of
melanocytes (Tolleson, 2005). Although cutaneous melanoma
represents o5% of all skin cancers, it is responsible for the
majority of skin cancer–related deaths. Environmental factors,
such as sun exposure, together with genetic predisposition,
such as fair complexion, red hair, and multiple nevi, appear to
contribute to melanoma development (Chudnovsky et al.,
2005). Cutaneous melanomas harbor a high frequency of
activating mutations in oncogenes, such as BRAF, NRAS, and
c-KIT; loss of tumor suppressors, such as CDKN2A and PTEN
(Populo et al., 2012), and also harbor the recently discovered
TERT promoter mutations (Horn et al., 2013; Huang et al.,
2013; Vinagre et al., 2013).
BCC represents the most common skin tumor, and BCC
incidence is increasing (Dessinioti et al., 2011). BCCs are
highly proliferative tumors that rarely metastasize; however,
these tumors can be highly invasive with locally destructive
growth and high morbidity (O’Driscoll et al., 2006). Characteri-
stic BCC mutations are ascribed to a small number of genetic
markers; notably, Patched 1 (PTCH1) and p53 mutations are
frequently noted with a prevalence of 67% (Reifenberger
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et al., 2005) and 50% (Rady et al., 1992), respectively.
Recently, 56–78% of TERT promoter mutations were
also described in BCC (Griewank et al., 2013; Scott et al.,
2013). Interestingly, approximately half of the reported
PTCH1 mutations correspond to UV-associated transitions
(Reifenberger et al., 2005), similar to TERT promoter
mutations observed in cutaneous skin cancer. The best-
defined carcinogenic factors for BCC are solar (Reifenberger
et al., 2005) and ionizing radiation exposure (Hassanpour
et al., 2006; Tessone et al., 2012). BCCs in the ionizing
radiation context are described as more prevalent, aggressive,
frequently recurring, and difficult to treat (Hassanpour et al.,
2006; Boaventura et al., 2012; Tessone et al., 2012). To date,
these differences have not been associated with any specific
mutational pattern (Tessone et al., 2012). To the best of our
knowledge, different carcinogenic factors (e.g., UV or X-ray
radiation) have not been addressed in TERT promoter
mutations in BCC.
In this study, we assessed TERT promoter mutations in
cutaneous cancers. We studied clinicopathological and mole-
cular features of cutaneous melanomas (n¼ 116), BCCs in
X-irradiated patients (n¼102), and BCCs in nonirradiated
patients (n¼94). We sought to determine whether TERT
promoter mutations are associated with UV and/or irradiation,




In total, 116 cutaneous melanoma cases were analyzed for
TERT promoter mutations. This series included 56 patients
enrolled in our last study (Vinagre et al., 2013). TERT promoter
mutations were present in 26 of 116 (22%) melanomas. The
following mutations were detected: 124:G4A mutation in
12 of 26 (46%) cases, 146:G4A mutation in 9 of 26 (35%)
cases, the tandem mutation  138/ 139:GG4AA in 2 cases
(8%), and the tandem mutation at position 124/125 in
three cases (11%). Fifteen of 26 (58%) melanomas with TERT
promoter mutations also harbored the BRAFV600E mutation.
In contrast, the BRAF mutation was present in 23 of 90 (25%)
melanomas without TERT mutations (Po0.01; Table 1). More-
over, TERT mutations were identified in 23 of 89 cases with
sun exposure, but in only 3 of 26 cases without sun exposure.
All of the 23 mutations occurred in cases with intermittent sun
exposure (n¼ 73), and no mutations were detected in 16 cases
with chronic sun exposure (Po0.01). TERT promoter muta-
tions were detected in nodular (9/21) and superficial spreading
melanoma (14/61) subtypes; however, only 3 of 22 acral
melanoma cases harbored this alteration (P¼ 0.03; Table 1).
TERT mutations were more frequent in tumors with increased
thickness (22 of 26, 85%) than in cases with reduced thickness
(4 of 26, 15%; P¼0.02). TERT mutations were more frequent
in tumors with epidermal ulceration (14 of 41, 34%) than in
cases without ulceration (12 of 75, 16%; P¼0.03). In
addition, TERT mutations were more frequent in tumors with
increased mitotic rates (22 of 77, 29%) than in cases with
reduced mitotic rates (4 of 39, 10%; P¼ 0.03). No significant
association was found between TERT mutations and other
clinicopathological parameters (age, sex, and pT category).To
evaluate whether TERT mutations correlate with disease-free
(DFS) and overall (OS) survival in cutaneous melanoma,
Kaplan–Meier curves were constructed using the average
follow-up time, as this is a retrospective study that includes
cases from 1982 to 2013. A significant association between
TERT mutations and DFS and OS was observed. Patients with
tumors harboring TERT mutations displayed reduced DFS (85
months, SE±11.43, 95% CI 62.61–107.44) and reduced OS
(86 months, SE±11.21, 95% CI 63.66–107.60), compared
with patients with tumors lacking TERT mutations (158
months, SE±8.91, 95% CI 140.17–175.11, and 165 months,
SE±9.17, 95% CI 147.46–183.39, respectively; P¼0.04;
Table 1. Melanoma clinicopathological features and







Number of cases (n) 116 90 26 —
Age at diagnosis
(mean (±SD))
60.0 (17.4) 60.0 (17.9) 59.2 (15.7) —
Gender (n (%))
Female 67 (57.8) 54 (60.0) 13 (50.0) —
Male 49 (42.2) 36 (40.0) 13 (50.0) 0.38
Histological subtype (n (%))
ALM 22 (19.0) 19 (21.1) 3 (11.5) —
LMM 12 (10.3) 12 (13.3) 0 (0) —
NM 21 (18.1) 12 (13.3) 9 (34.6) —
SSM 61 (52.6) 47 (52.3) 14 (53.9) 0.03
Median thickness (mm
(range))
4.0 (0–70) 2.9 (0–19) 8.1 (0–70) 0.02
Epidermal ulceration (n (%))
Absent 75 (64.7) 63 (70.0) 12 (46.2) —
Present 41 (35.3) 27 (30.0) 14 (53.8) 0.03
Mitotic rate (n (%))
o1 mm2 39 (33.6) 35 (38.9) 4 (15.4) —
X1 mm2 77 (66.4) 55 (61.1) 22 (84.6) 0.03
pT (n (%))
ppT2 55 (47.8) 47 (52.8) 8 (30.8) —
4pT2 60 (52.2) 42 (47.2) 18 (69.2) 0.07
Sun exposure (n (%))
Absent 26 (22.6) 23 (25.8) 3 (11.5) —
Intermittent 73 (63.5) 50 (56.2) 23 (88.5) —
Chronic 16 (13.9) 16 (18.0) 0 o0.01
BRAF status
wt 78 (67.2) 67 (74.4) 11 (42.3) —
V600E 38 (32.8) 23 (25.6) 15 (57.7) o0.01
Abbreviations: ALM, acral lentiginous melanoma; LMM, lentigo maligna
melanoma; mut, mutation; NM, nodular melanoma; SSM, superficial
spreading melanoma; TERT, telomerase; wt, wild type.
Bold values indicate significant P-values.
H Po´pulo et al.
TERT Mutations in BCC and Melanoma
2252 Journal of Investigative Dermatology (2014), Volume 134
Figure 1). The correlation was also observed by the univariate
Cox regression analysis for both DFS and OS (P¼0.04;
Table 2). No correlation was observed in the multivariate
analysis (Supplementary Table S1 online).
TERT expression was nuclear and cytoplasmic in 98% of
cutaneous melanomas. No difference in TERT expression
levels was observed between tumors with and without TERT
promoter mutations; however, the superficial spreading mel-
anoma subtype displayed an increased mean expression level
(10.53, SD±6.24) compared with lentigo maligna (4.17,
SD±4.75), acral (8.71, SD±3.47), and nodular (7.83,
SD±3.21) melanoma subtypes (P¼ 0.02; Figure 2). No
correlation was observed between TERT expression levels
and the clinicopathological parameters of the cutaneous
melanomas, namely DFS or OS.
BCC
TERT promoter mutations were present in 76 of 196 total BCC
cases (39%), 28 of 102 (27%) BCCs from X-irradiated patients,
and 48 of 94 (51%) BCCs from non-X-irradiated patients, this
difference being statistically significant (Po0.01). The
 124:G4A mutation was present in 37 of 76 mutated BCCs
Table 2. Disease-free and overall survival univariate Cox regression analysis in cutaneous melanomas
Disease-free survival Overall survival
Clinicopathological features Number of events (%) HR 95% CI P-value Number of events (%) HR 95% CI P-value
Epidermal ulceration
Absent 6 (8.6) 9.07 3.54–23.27 o0.01 5 (6.7) 13.10 4.84–35.47 o0.01
Present 17 (51.5) 20 (52.6)
Mitotic rate
o1 mm2 2 (5.1) 7.25 1.70–30.95 0.01 2 (5.1) 7.01 1.60–29.75 0.01
X1 mm2 21 (32.8) 23 (31.1)
Thickness
p1 mm 1 (2.7) 14.12 1.90–104. 67 0.01 1 (2.4) 15.18 2.05–112. 25 0.01
41 mm 22 (33.3) 24 (33.3)
pT
pTis/1/2 2 (4.2) 10.69 2.50–45.66 o0.01 2 (3.9) 10.79 2.54–45.81 o0.01
pT3/4 21 (38.2) 23 (37.1)
TERT
wt 14 (17.9) 2.33 1.01–5.39 0.04 16 (18.2) 2.34 1.03–5.32 0.04
mut 9 (36.0) 9 (36.0)
Abbreviations: CI, confidence interval; HR, hazard ratio; TERT, telomerase.
Bold values indicate significant P-values.
Number at risk Number at risk
TERTmut 25 10 1 0








































0 50 100 150
Time (months)





1 TERTwt 88 48 13 1 1
TERTmut 25 11 1 0 0
Figure 1. Kaplan–Meier curves for disease-free and overall survival of cutaneous melanoma patients. Kaplan–Meier curves demonstrating the correlation
between telomerase (TERT) promoter mutations and disease-free (a) and overall (b) survival of cutaneous melanoma patients. Patients with TERT promoter
mutations (solid line) display significantly (P¼ 0.04) reduced disease-free and overall survival compared with patients without TERT mutations (dashed line).
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(49%). The 146:G4A mutation was present in 33 of 76
BCCs (43%). The tandem mutation at position  138/ 139
was observed in two BCCs (3%), and the tandem mutation at
position 124/ 125 was observed in two BCCs (3%).
Moreover, two BCCs simultaneously harbored  124:G4A
and 146:G4A mutations (3%; Table 3). In addition to the
significantly increased frequency of TERT promoter mutations
in non-X-irradiated BCC patients, we observed a significant
difference in the prevalence of the two most frequent muta-
tions based on radiation exposure. The  124:G4A mutation
was more frequent in tumors from nonirradiated patients
compared with those from irradiated patients (62 vs. 25%),
whereas the  146:G4A mutation was more frequent in
tumors from X-irradiated patients compared with those from
nonirradiated patients (75 vs. 25%; Po0.01; Table 3).
In the entire BCC series, no correlation was observed
between TERT promoter mutations and clinicopathological
features (gender, age at diagnosis, histological subtype, single
or multiple BCCs, localization, and sun exposure; Table 4).
However, with regard to BCCs from non-X-irradiated patients,
TERT promoter mutations were significantly more frequent in
BCCs localized to sun-exposed areas compared with tumors
from sun-protected areas (63 vs. 31%, Po0.01) and less
frequent in scalp BCCs (a sun-protected area) compared with
other locations (27 vs.58%, P¼0.03). No additional correla-
tions were observed between TERT promoter mutations and
other clinicopathological parameters when BCCs from irra-
diated or nonirradiated patients were separately considered.
Nuclear and cytoplasmic TERT expression was detected in
93% of the BCCs. No difference in TERT immunohistochem-
ical expression levels was observed between BCCs with and
without TERT promoter mutations. No correlation was
observed between TERT expression levels and BCC clinico-
pathological parameters.
DISCUSSION
We report a high frequency of TERT promoter mutations in a
large series of BCCs with distinct carcinogenic factors (UV or
X-ray radiation). TERT promoter mutations were found in 39%
of the entire BCC series. Moreover, 51% of BCCs from non-X-
irradiated patients harbor TERT promoter mutations. This result
is lower than the rate of 78% reported by Scott et al. (Scott
et al., 2013); however, our findings are consistent with the rate
(56%) reported by Griewank et al. (Griewank et al., 2013) in a
series of 32 BCCs. A lower prevalence (22%) of mutations was
detected in cutaneous melanoma. Melanoma and BCC share a
common carcinogenic factor: solar exposure (Chudnovsky
et al., 2005). Ionizing radiation exposure is carcinogenic in
BCC but not in melanoma (Dessinioti et al., 2011; Populo
et al., 2012). We evaluated whether UV radiation and X-ray
irradiation associate with distinct TERT mutations. Huang
et al. (Huang et al., 2013) and Horn et al. (Horn et al.,
2013) suggested that TERT promoter mutations result from UV
radiation–induced damage. In the present study, we demon-
strate that TERT promoter mutations associate with cutaneous
cancers occurring in sun-exposed areas. Notably, BCCs from
non-X-irradiated patients, localized to sun-exposed skin, and
melanomas occurring in intermittent sun-exposed skin dis-
played an increased prevalence of TERT promoter mutations
compared with melanomas occurring in sun-protected
areas.The significant lower prevalence of TERT promoter
mutations in BCCs from X-irradiated patients together
with our results in post-Chernobyl thyroid tumors (Melo
et al., 2014) that do not show these alterations suggest that
ionizing irradiation is not a strong ethiopathogenic factor for
TERT promoter mutations.
We found that the two mutated hotspots were not evenly
distributed between BCC X-irradiated versus nonirradiated
patients. The 124:G4A mutation was significantly more
a b
c
0 50 100 150 200µm 0 50 100 150 200µm
0 50 100 150 200µm 0 50 100 150 200µm
d
Figure 2. Telomerase expression in melanoma. Telomerase (TERT) expression in acral (a), lentigo maligna (b), nodular (c), and superficial spreading (d) melanoma
subtypes. DAB. Scale bars¼ 200mm (a–d).
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frequent in BCCs from nonirradiated patients, whereas
the 146:G4A mutation was significantly more frequent in
BCCs from X-irradiated patients. These findings indicate that
X-ray ionizing radiation leads to a distinct mutation pattern
that is potentially attributed to unknown differing pathogenic
mechanisms. The 124:G4A mutation also showed a higher
frequency in sporadic melanomas, where the primary carci-
nogenic factor is UV exposition. TERT promoter mutations
were not associated with other clinicopathological parameters
in BCC.
Melanoma is found more frequently in intermittently sun-
exposed skin than in nonexposed and chronically exposed
skin (Tolleson, 2005). In line with the epidemiological data,
TERT promoter mutations were also more frequent in
melanomas occurring in intermittent sun-exposed skin
compared with nonexposed and chronically exposed skin.
Interestingly, TERT mutations were more prevalent in nodular
and superficial spreading melanomas, which typically occur
in intermittent sun-exposed skin. A higher prevalence of TERT
mutations was described in metastatic melanoma samples (77
to 85%) than in primary melanomas (33%; Horn et al., 2013;
Huang et al., 2013). Differences in melanoma subtypes
included in different series, the inclusion of primary versus
metastatic melanoma samples, and the size of the series may
explain the variation in the mutation frequency reported in our
study that includes 116 primary melanomas (22%).
We observed associations between TERT promoter muta-
tions and increased thickness, ulceration, and increased
mitotic rate, all of which are poor prognostic indicators of
melanoma. Furthermore, Kaplan–Meier and univariate Cox
regression analyses indicated that TERT promoter mutations
potentially constitute a biological predictor of metastasis and
mortality, as already reported in glioblastoma, medulloblas-
toma, bladder, and thyroid cancers (Killela et al., 2013,
Rachakonda et al, 2013, Remke et al., 2013, Melo et al.,
2014). However, TERT promoter mutations cannot be con-
sidered an independently prognostic factor, regarding DFS and
OS, as in the multivariate model the presence of ulceration
became the only independent predictor for metastasis and
mortality. Therefore, a larger, independent study should be
conducted in order to confirm whether TERT promoter
mutations may constitute a biological predictor of poorer
prognosis in melanoma.
Using mRNA expression, we previously reported increased
levels of TERT expression in thyroid cancer cases harboring
TERT promoter and BRAF mutations (Vinagre et al., 2013).
Concordantly, we observed an association between TERT
Table 3. Clinicopathological features and TERT













Male 81 26 (32.1) 55 (67.9) —
Female 115 76 (66.1) 39 (33.9) o0.01
Age at diagnosis (mean
(±SD))
58.9±7.4 57.9±7.0 60.0±7.6 0.05
Localization (n (%))
Sun-exposed 101 (54.9) 39 (38.6) 62 (61.4) —
Sun-protected 83 (45.1) 54 (65.1) 29 (34.9) o0.01
BCC frequency (n (%))
Single BCC 78 (39.8) 29 (37.2) 49 (62.8) —
Multiple BCCs 118 (60.2) 73 (61.9) 45 (38.1) o0.01
BCC histotype
Nodular 86 (44.6) 40 (40.0) 46 (49.5) 0.19
Infiltrative 27 (14.0) 20 (20.0) 7 (7.5) 0.01
Superficial 19 (9.8) 12 (12.0) 7 (7.5) 0.30
Mixed 58 (30.1) 28 (28.0) 30 (32.3) 0.52
TERT mutation (n (%))
 124:G4A 37 (48.7) 7 (25.0) 30 (62.5) o0.01
 146:G4A 33 (43.4) 21 (75.0) 12 (25.0) —
 138/ 139:GG4AA 2 (2.6) 0 2 (4.2) —
 124:G4A/125:
G4A
2 (2.6) 0 2 (4.2) —
 124:G4A,  125:
G4A
2 (2.6) 0 2 (4.2) —
Total 76 (39.0) 28 (27.5) 48 (51.1) o0.01
Abbreviations: BCC, basal cell carcinoma; TERT, telomerase.
Bold values indicate significant P-values.
Table 4. Clinicopathological features and the







Number of cases (n) 196 120 76 —
Age at diagnosis
(mean (±SD))
58.4±7.4 61.4±9.0 58.5±5.8 0.06
Gender (n (%))
Female 115 (58.7) 72 (60.0) 43 (56.6) —
Male 81 (41.3) 48 (40.0) 33 (43.4) 0.64
Histological subtype (n (%))
Nodular 86 (44.6) 53 (44.9) 33 (44.0) 0.90
Infiltrative 27 (14.0) 16 (13.6) 11 (14.7) 0.83
Superficial 19 (9.8) 14 (11.9) 5 (6.7) 0.24
Mixed 58 (30.1) 34 (28.8) 24 (32.0) 0.64
BCC frequency (n (%))
Single BCC 78 (39.8) 42 (35.0) 36 (47.4) —
Multiple BCCs 118 (60.2) 78 (65.0) 40 (52.6) 0.09
Localization (n (%))
Sun-exposed 101 (54.9) 55 (50.0) 46 (62.2) —
Sun-protected 83 (45.1) 55 (50.0) 28 (37.8) 0.10
Abbreviations: BCC, basal cell carcinoma; TERT, telomerase.
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promoter mutations and BRAFV600E mutations in our
melanoma series. Recently, an association between TERT
promoter mutations and FGFR3 in bladder cancer was also
reported (Allory et al., 2013). Similar to the aforementioned
cancer types, we speculate that other oncogenic events (e.g.,
PTCH1 mutations) may occur in a subset of tumors and may
act as additional events that potentiate TERT expression in
promoter-mutated cases in BCC.
To our knowledge, TERT promoter mutations have not been
studied in cutaneous BCC in the context of ionizing radiation
exposure. Our melanoma and BCC results confirm that TERT
promoter mutations are frequent in skin cancers. Notably, our
results highlight a putative UV signature in skin cancers
with intermittent sun exposure that is distinct from ionizing
irradiation.
MATERIALS AND METHODS
Sample selection, clinicopathological, and prognostic
parameters
The study procedures are in accordance with institutional ethical
standards. Formalin-fixed, paraffin-embedded tissues from 116
sporadic cutaneous melanomas were retrieved from the files of the
Department of Pathology of Hospital S. Joa˜o (HSJ), Porto; the
Department of Pathology of Hospital S. Marcos (HSM), Braga; and
the IPATIMUP, Porto (56 cases were previously reported (Vinagre
et al., 2013)). Clinicopathological and follow-up data were retrieved
from the files of the Department of Pathology, Department of
Dermatology and Oncology Registry of HSJ, Department of
Pathology of HSM, and from RORENO (Oncology Registry of North
Region). All melanomas collected were diagnosed between 1982 and
2013, and the cases were reevaluated and staged according to AJCC
guidelines (Balch et al., 2009). Table 1 summarizes the collected
data. Follow-up data were obtained through patient evaluation, direct
interviews with relatives, or in-hospital patient file review. It includes
the diagnosis of recurrences and metastases (DFS), available for 103
patients, and the number of deaths attributable to the melanoma
(disease-specific mortality; OS), available for 113 patients. The mean
follow-up time of the patients for DFS was 54 months (SE±3.95,
range 1–195) and for OS it was 57 months (SE±3.74, range 1–207).
The total follow-up for all the melanoma patients was 459.8 person-
years for DFS and 535.8 person-years for OS. During the follow-up,
19 (17%) patients developed (lymph node, liver, or brain) metastases,
4 (3%) patients experienced local tumor recurrence, and 25 (22%)
patients died because of their malignant tumors. The disease-specific
mortality rate was 46.7 per 1,000 person-years. The remaining patients
were alive without evidence of melanoma recurrence at the last
follow-up or deceased from unrelated causes. With regard to BCC, we
retrieved 102 BCCs from 61 irradiated patients (1.67 lesions per
patient) including 56 individuals who underwent X-ray scalp epilation
during childhood (Boaventura et al., 2011) and five adult patients
who received radiotherapy for cancer treatment. In the nonirradiated
group, we reviewed 94 BCC tumors from 70 patients (1.34 lesions per
patient) who had never been exposed to any radiation treatment;
these cases were collected as a consecutive series (2009 to 2013)
from Hospital Pedro Hispano, Matosinhos. In total, we collected and
reviewed 196 formalin-fixed, paraffin-embedded specimens from 131
patients with clinical follow-up. A clinical history, including past
irradiation treatments, was obtained in every case.
The evaluation of previous X-ray irradiation was only performed in
patients with BCC given that melanomas were rarely diagnosed in the
irradiated cohort.
Immunohistochemical analysis
Immunohistochemistry procedures were performed as previously
described (Vinagre et al., 2013). Two observers (JML and HP)
blinded to any clinical information regarding the cases evaluated
the immunohistochemistry results. The immunoreactivity score was
established as a product of the intensity of staining (0: absent, 1: faint,
2: moderate, or 3: strong) with the percentage of cells demonstrating a
positive reaction (0: 0%, 1: 1–25%, 2: 25–50, 3: 50–75, and 4:
475%), as previously reported (Populo et al., 2010; Vinagre et al.,
2013). Negative and positive controls were simultaneously used to
ensure the specificity and reliability of the staining process. Previously
tested positive cases of solid cell nest (Preto et al., 2004) and gastric
tumor were used as positive controls. Negative controls were
produced by omitting the primary antibody incubation.
DNA extraction and mutation analysis
Melanomas larger than 5 mm and BCCs were manually dissected
from 10-mm whole sections of paraffin-embedded material, before
DNA extraction using the Invisorb spin tissue mini kit (Invitek, Berlin,
Germany). For melanomas smaller than 5 mm, laser microdissection
of 3-mm sections of paraffin-embedded tissue was performed using the
PALM MicroLaser Systems (PALM, Bernried, Germany), and DNA
was extracted using the Quiamp DNA micro kit (Quiagen, Hilden,
Germany) according to the manufacturer’s instructions. Genomic
DNA (25–100 ng) was amplified by PCR using the following cycling
conditions: 35 s at 94 1C; 40 s at 62 1C for TERT or 58 1C for BRAF;
and 45 s at 72 1C for 40 cycles. Primers can be found in our previous
report (Vinagre et al., 2013). Products were enzymatically purified
and directly sequenced in an ABI Prism 3130 xl Automatic sequencer
(Perkin-Elmer, Foster City, CA) using the BigDye Terminator
Sequencing kit (Perkin-Elmer). Cases with mutations were confirmed.
Statistical analysis
Statistical analyses were performed using STAT VIEW-J 5.0 (SAS
Institute, Cary, NC). The relationship between the mutation and the
clinicopathological parameters (presented in Table 1) was evaluated
using Fisher’s exact test. The relationship between the average
expression level (score) of the immunohistochemistry marker and
clinicopathological parameters was evaluated by ANOVA. When
appropriate, multiple comparison corrections were performed using
the post hoc Bonferroni and Tamhane tests. The Kaplan–Meier
method and log-rank test were used to evaluate the melanoma
survival data. Univariate and multivariate analyses were performed
to determine the prognostic value of covariates regarding OS and DFS
using the Cox regression model. All the variables significantly
associated with the specified outcome in the univariate model were
included in the multivariate analyses. OS and DFS were calculated
from the time of diagnosis until death due to disease or metastasis,
respectively, or censored at the time of the latest follow-up or death
unrelated to the disease. A P-valueo0.05 was considered statistically
significant.
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